Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 02209/UN4.22/PT.01.03/2025 | Other Grant/Funding Number | BIMA Research Grant 2025 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this randomized controlled trial is to learn if GlucoBites functional cookies containing Gynura procumbens can help improve blood sugar control and lower the risk of diabetic foot ulcers in adults with type 2 diabetes.
The main questions are:
Researchers will compare:
Participants will:
This study will help determine if a functional food innovation can support diabetes care and prevent complications.
Type 2 diabetes mellitus is a chronic condition associated with serious complications, including neuropathy and diabetic foot ulcers. Many people in Indonesia still struggle with poor blood sugar control despite standard treatments. This highlights the need for safe, affordable, and culturally acceptable nutritional strategies.
This study is testing GlucoBites, a functional cookie made with Gynura procumbens, a traditional medicinal plant with potential glucose-lowering and vascular protective properties. Researchers want to see if adding GlucoBites to daily care can improve blood sugar control and reduce early risk factors linked to diabetic foot ulcer development.
The study will help determine whether functional food innovation can be integrated into community-based diabetes management and offer a preventive approach to reduce long-term complications.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control Cookies (without Gynura procumbens) | Placebo Comparator | Participants receive 4 cookies per day for 12 weeks. The cookies are identical in packaging, size, weight, and flavor but do not contain Gynura procumbens. |
|
| GlucoBites (with Gynura procumbens) | Experimental | Participants receive 4 cookies per day for 12 weeks. The cookies contain standardized Gynura procumbens extract. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GlucoBites (with Gynura procumbens) | Dietary Supplement | Participants receive 4 cookies per day for 12 weeks. The cookies contain standardized Gynura procumbens extract. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Fasting Blood Glucose (FBG) | Fasting blood glucose (FBG, mg/dL) measured from venous blood after 8-10 hours of fasting using standardized laboratory methods. The primary endpoint is the change from baseline to Week 12, comparing the GlucoBites group (with Gynura procumbens) and the control group (without Gynura procumbens). | Baseline and 12 weeks after intervention |
| Change in HOMA-IR | Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) calculated from fasting glucose (mg/dL) and fasting insulin (µIU/mL) using the formula: [fasting insulin × fasting glucose / 405]. The endpoint is the change in HOMA-IR from baseline to Week 12, comparing the GlucoBites group (with Gynura procumbens) and the control group (without Gynura procumbens). | Baseline and 12 weeks after intervention |
| MMP-9/TIMP-1 Ratio | The ratio of matrix metalloproteinase-9 (MMP-9) to tissue inhibitor of metalloproteinase-1 (TIMP-1) in serum, quantified using ELISA. The ratio is calculated by dividing MMP-9 (ng/mL) by TIMP-1 (ng/mL). The endpoint is the change in MMP-9/TIMP-1 ratio from baseline to Week 12, comparing the GlucoBites group (with Gynura procumbens) and the control group (without Gynura procumbens). | Baseline and 12 weeks after intervention |
| Ankle-Brachial Index (ABI) | The ankle-brachial index (ABI) is calculated as the ratio of systolic blood pressure measured at the ankle to systolic blood pressure measured at the brachial artery. Measurements are obtained using a handheld Doppler device. ABI will be used as an indicator of peripheral vascular function and early risk of diabetic foot ulcer. The endpoint is the change in ABI from baseline to Week 12, comparing the GlucoBites group (with Gynura procumbens) and the control group (without Gynura procumbens). | Baseline and 12 weeks after intervention |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andina Setyawati, Dr | Contact | +628121521639 | andina@unhas.ac.id |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Public Health Centre of Campagaloe | Bantaeng | South Sulawesi | 92411 | Indonesia |
Not provided
| Label | URL |
|---|---|
| Original research article reporting the antidiabetic effects of Gynura procumbens on pancreatic histopathology via caspase family expression in diabetic rat models, published in the Journal of Pharmacy \& Pharmacognosy Research (2025). | View source |
Not provided
Individual participant data (IPD) underlying the published results will be made available in anonymized form. The data will be accessible upon reasonable request to the corresponding investigator after publication, in accordance with ethical approval and institutional policies
IPD and supporting documents (study protocol, statistical analysis plan, and informed consent form) will be available within 6 months after publication of the main results and will remain available for 5 years
De-identified individual participant data (IPD) and supporting documents will be available to qualified researchers for academic and scientific purposes. Access will be granted upon reasonable request to the sponsor or principal investigator, subject to approval of a data use agreement
Not provided
Not provided
This randomized controlled trial uses a parallel assignment model with two study arms. Participants will be randomly allocated to either the intervention group receiving GlucoBites functional cookies containing Gynura procumbens or the control group receiving standard diabetes care. Both groups will be followed simultaneously for 12 weeks.
Not provided
Not provided
Participants in both arms receive visually identical cookies. The experimental cookies contain Gynura procumbens extract, while the control cookies do not. Packaging, appearance, weight, and flavor are matched. Randomization codes are held by an independent pharmacist/allocator; care providers and outcomes assessors are blinded to group assignment. Unblinding will occur only after database lock or for safety reasons.
|
| Control Cookies (without Gynura procumbens) | Dietary Supplement | Participants consume 4 cookies per day for 12 weeks. The cookies are identical in packaging, size, weight, and flavor to the GlucoBites cookies but do not contain Gynura procumbens. |
|
|
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D003929 | Diabetic Neuropathies |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D048909 | Diabetes Complications |
| D006946 | Hyperinsulinism |
Not provided
Not provided